Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.
Florence OberkampfMaya GutierrezOlfa Trabelsi GratiÉmilie Le RhunOlivier TrédanIsabelle TurbiezAmir KadiCoraline DubotSophie TaillibertSophie VacherClaire BonneauPublished in: Neuro-oncology (2022)
Conducting studies on patients with LM poses significant challenges and ethical dilemmas inherent to this population. Despite some limits, this phase II study's findings in terms of clinical neurologic response and quality of life's control confirms weekly administration of 150 mg of IT trastuzumab as a valuable option for HER+BC patients with LM and support the interest for further investigations.
Keyphrases
- phase ii study
- positive breast cancer
- open label
- epidermal growth factor receptor
- locally advanced
- metastatic breast cancer
- placebo controlled
- squamous cell carcinoma
- rectal cancer
- cerebrospinal fluid
- clinical trial
- randomized controlled trial
- tyrosine kinase
- small cell lung cancer
- radiation therapy
- brain metastases